-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Downgrades Soleno Therapeutics to Neutral, Lowers Price Target to $53

Benzinga·04/08/2026 11:03:12
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Soleno Therapeutics (NASDAQ:SLNO) from Buy to Neutral and lowers the price target from $100 to $53.